Preclinical studies have demonstrated that BRCA2-deficient pancreatic cancer cells are markedly more sensitive to the PARP inhibitor Talazoparib, both in vitro and in mouse xenograft models [210]. Here, BRCA2 is linked to familial pancreatic carcinoma.